Physician profile
Mara Leyzin
NPI 1003992579
$1,476.25
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $381 · 2021: $452 · 2022: $160.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $468.12 | 2019-2022 | |
| Abbvie INC. | $231.61 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.74 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $100.00 | 2019 | |
| Novo Nordisk INC | $91.41 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $82.85 | 2021 | |
| Pfizer INC. | $59.45 | 2019-2022 | |
| Allergan, INC. | $44.18 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $43.73 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $41.80 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $34.77 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $33.43 | 2020 | |
| Astellas Pharma US INC | $32.95 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $28.88 | 2020-2021 | |
| Amgen INC. | $19.92 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.47 | 2019 | |
| Amarin Pharma, INC. | $15.35 | 2021 | |
| Avion Pharmaceuticals | $13.03 | 2020 | |
| Janssen Biotech, INC. | $12.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Leyzin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.